Alcántara Roberto, Fuentes Patricia, Marin Lisette, Kirwan Daniela E, Gilman Robert H, Zimic Mirko, Sheen Patricia
Laboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú
Laboratorio de Bioinformática y Biología Molecular, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Perú.
J Clin Microbiol. 2020 Apr 23;58(5). doi: 10.1128/JCM.01165-19.
Pyrazinamide (PZA) is considered the pivot drug in all tuberculosis treatment regimens due to its particular action on the persistent forms of However, no drug susceptibility test (DST) is considered sufficiently reliable for routine application. Although molecular tests are endorsed, their application is limited to known PZA resistance associated mutations. Microbiological DSTs for PZA have been restricted by technical limitations, especially the necessity for an acidic pH. Here, for the first time, MODS culture at neutral pH was evaluated using high PZA concentrations (400 and 800 μg/ml) to determine PZA susceptibility directly from sputum samples. Sputum samples were cultured with PZA for up to 21 days at 37°C. Plate reading was performed at two time points: R1 (mean, 10 days) and R2 (mean, 13 days) for each PZA concentration. A consensus reference test, composed of MGIT-PZA, sequencing, and the classic Wayne test, was used. A total of 182 samples were evaluated. The sensitivity and specificity for 400 μg/ml ranged from 76.9 to 89.7 and from 93.0 to 97.9%, respectively, and for 800 μg/ml ranged from 71.8 to 82.1 and from 95.8 to 98.6%, respectively. Compared to MGIT-PZA, our test showed a similar turnaround time (medians of 10 and 12 days for PZA-sensitive and -resistant isolates, respectively). In conclusion, MODS-PZA is presented as a fast, simple, and low-cost DST that could complement the MODS assay to evaluate resistance to the principal first-line antituberculosis drugs. Further optimization of test conditions would be useful in order to increase its performance.
吡嗪酰胺(PZA)因其对结核分枝杆菌持续菌型的特殊作用,被认为是所有结核病治疗方案中的关键药物。然而,目前尚无药物敏感性试验(DST)被认为足够可靠用于常规应用。尽管分子检测得到认可,但其应用仅限于已知的与PZA耐药相关的突变。PZA的微生物学DST受到技术限制,特别是需要酸性pH环境。在此,首次使用高浓度PZA(400和800μg/ml)在中性pH下进行改良罗氏培养法(MODS),以直接从痰液样本中确定PZA敏感性。痰液样本与PZA在37°C下培养长达21天。在两个时间点进行平板读数:每个PZA浓度下的R1(平均10天)和R2(平均13天)。使用由分枝杆菌生长指示管-PZA(MGIT-PZA)、测序和经典韦恩试验组成的一致性参考试验。共评估了182个样本。400μg/ml时的敏感性和特异性分别为76.9%至89.7%和93.0%至97.9%,800μg/ml时分别为71.8%至82.1%和95.8%至98.6%。与MGIT-PZA相比,我们的试验显示出类似的周转时间(PZA敏感和耐药菌株的中位数分别为10天和12天)。总之,MODS-PZA是一种快速、简单且低成本的DST,可补充MODS检测以评估对主要一线抗结核药物的耐药性。进一步优化试验条件将有助于提高其性能。